Meeting
2021 ASCO Annual Meeting
A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.
Authors
Richard D. Kim
Moffitt Cancer Center, Tampa, FL
Richard D. Kim , James M. Cleary , Alexis Diane Leal , Aparna Raj Parikh , David P. Ryan , Shining Wang , Brittany Bahamon , Neeraj Gupta , Aaron Moss , Joanna Pye , Harry H. Miao , Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Immunoconjugates (non-IO)
Clinical Trial Registration Number
NCT03449030
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3050)
DOI
10.1200/JCO.2021.39.15_suppl.3050
Abstract #
3050
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.
First Author: Ying Cheng
Poster
2021 ASCO Annual Meeting
Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
First Author: David Starks
Poster
2020 ASCO Virtual Scientific Program
First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
First Author: Yeon Hee Park
Poster
2015 ASCO Annual Meeting
Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.
First Author: David Shao Peng Tan